News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Amarantus BioSciences, Inc. Engages BD Biosciences (BDX) for Development of Alzheimer's Diagnostic


6/13/2013 10:14:31 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

SUNNYVALE, Calif.--(BUSINESS WIRE)--Amarantus BioScience Holdings, Inc. (OTCQB: AMBS), a biotechnology company discovering and developing treatments and diagnostics for diseases associated with neurodegeneration and apoptosis, today announced it has signed a laboratory services agreement with BD Biosciences, a segment of BD (Becton, Dickinson and Company) , a leading global medical technology company, under which BD’s BD Biosciences Custom Technology Team will perform sample analysis on Amarantus’ LymPro Test® for Alzheimer’s disease. Financial terms were not disclosed.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES